A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT ID: NCT02031458
Last Updated: 2020-01-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
667 participants
INTERVENTIONAL
2014-01-22
2019-01-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
NCT01846416
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT03735121
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
NCT02008227
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
NCT03191786
A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer
NCT02848651
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atezolizumab
Atezolizumab
1200 mg IV every 3 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab
1200 mg IV every 3 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC
* Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens
* PD-L1-positive tumor status as determined by an immunohistochemistry (IHC) assay based on PD-L1 expression on tumor infiltrating immune cells and/or tumor cells performed by a central laboratory
* Measurable disease, as defined by RECIST version 1.1
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria
Hormone-replacement therapy or oral contraceptives tyrosine-kinase inhibitors (TKIs) approved for treatment of NSCLC discontinued \>7 days prior to Cycle 1, Day 1
* Central nervous system (CNS) disease, including treated brain metastases
* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with negligible risk of metastases or death and treated with expected curative outcome
* History of autoimmune disease
* History of idiopathic pulmonary fibrosis (including pneumonia), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening CT scan. History of radiation pneumonitis in the radiation field (fibrosis) id permitted
* Active hepatitis B or hepatitis C
* Human Immunodeficiency virus (HIV) positive
* Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
HonorHealth Research Institute - Bisgrove
Scottsdale, Arizona, United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Angeles Clinic & Rsch Inst
Los Angeles, California, United States
City of Hope National Medical Group
South Pasadena, California, United States
Stanford Cancer Center
Stanford, California, United States
University of Colorado Health Science Center; Biomedical Research Bldg. Room 511
Aurora, Colorado, United States
Yale Cancer Center; Medical Oncology
New Haven, Connecticut, United States
Georgetown University Medical Center Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Florida Cancer Specialists; SCRI
Fort Myers, Florida, United States
Florida Hospital Cancer Inst
Orlando, Florida, United States
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, United States
Florida Cancer Specialists.
St. Petersburg, Florida, United States
Emory Uni - Winship Cancer Center; Hematology/Oncology
Atlanta, Georgia, United States
Northwest Georgia Oncology Centers PC - Marietta
Marietta, Georgia, United States
Northwestern University; Robert H. Lurie Comp Can Ctr
Chicago, Illinois, United States
University Of Chicago Medical Center; Section Of Hematology/Oncology
Chicago, Illinois, United States
Uni of Maryland; Greenebaum Cancer Center
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Beth Israel Deaconess Med Ctr; Hem/Onc
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Washington University School of Medicine
St Louis, Missouri, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Monter Cancer Center
Lake Success, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Carolina BioOncology Institute, PLCC
Huntersville, North Carolina, United States
Oncology Hematology Care Inc
Cincinnati, Ohio, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
Ohio State University; B406 Starling-Loving Hall
Columbus, Ohio, United States
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
Fox Chase Cancer Center; Hematology/Oncology
Philadelphia, Pennsylvania, United States
Tennessee Oncology PLLC - Nashville (20th Ave)
Nashville, Tennessee, United States
MD Anderson Cancer Center
Houston, Texas, United States
Huntsman Cancer Institute; University of Utah
Salt Lake City, Utah, United States
University of Virginia; Office of Sponsored Programs
Charlottesville, Virginia, United States
University of Washington Seattle Cancer Care Alliance
Seattle, Washington, United States
University of Wisconsin
Madison, Wisconsin, United States
Royal North Shore Hospital; Oncology
St Leonards, New South Wales, Australia
Princess AleXandra Hospital; Department of Medical Oncology
Woolloongabba, Queensland, Australia
Austin Health
Heidelberg, Victoria, Australia
Peter Maccallum Cancer Institute; Medical Oncology
Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital; Medical Oncology
Nedlands, Western Australia, Australia
Cliniques Universitaires St-Luc
Brussels, , Belgium
GHdC Site Saint-Joseph
Charleroi, , Belgium
UZ Leuven Gasthuisberg
Leuven, , Belgium
Sint Augustinus Wilrijk
Wilrijk, , Belgium
University Clinical Centre of the Republic of Srpska
Banja Luka, , Bosnia and Herzegovina
University Clinical Center Sarajevo;Clinic for Pulmonary disease
Sarajevo, , Bosnia and Herzegovina
University Clinical Center Sarajevo;Institute of oncology
Sarajevo, , Bosnia and Herzegovina
Complex Oncology Center (COC)-Plovidiv
Plovdiv, , Bulgaria
Specialized Hospital for Active Treatment of Oncology
Sofia, , Bulgaria
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, Canada
Lakeridge Health Oshawa; Oncology
Oshawa, Ontario, Canada
The Ottawa Hospital Cancer Centre; Oncology
Ottawa, Ontario, Canada
Sunnybrook Odette Cancer Centre
Toronto, Ontario, Canada
University Health Network; Princess Margaret Hospital; Medical Oncology Dept
Toronto, Ontario, Canada
Hopital Augustin Morvan; Oncologie Thoracique
Brest, , France
Hopital Cote De Nacre; Pneumologie
Caen, , France
CHU Limoges - Dupuytren; Oncologie Thoracique Cutanee
Limoges, , France
Centre Leon Berard; Departement Oncologie Medicale
Lyon, , France
Hopital Arnaud De Villeneuve; Maladies Respiratoires
Montpellier, , France
Centre René Gauducheau - cancer Nantes - Atlantique; Service Oncologie Médicale
Nantes, , France
Nouvel Hopital Civil; Pneumologie
Strasbourg, , France
Institut Gustave Roussy; Departement Oncologie Medicale
Villejuif, , France
Research institute for Clinical Medicine
Tbilisi, , Georgia
Cancer Research Centre
Tbilisi, , Georgia
MediClab Georgia
Tbilisi, , Georgia
Chemotherapy and Immunotherapy Clinic Medulla
Tbilisi, , Georgia
Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung
Essen, , Germany
LungenClinic Großhansdorf GmbH
Großhansdorf, , Germany
Klinikum Nuernberg Nord; Medizinische Klinik 3, Schwerpunkt Pneumologie, Allergologie, Schlafmedizin
Nuremberg, , Germany
Pius-Hospital; Klinik fuer Haematologie und Onkologie
Oldenburg, , Germany
Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie
Villingen-Schwenningen, , Germany
Queen Elizabeth Hospital; Clinical Oncology
Hong Kong, , Hong Kong
Queen Mary Hospital; Dept. of Clinical Oncology
Hong Kong, , Hong Kong
Prince of Wales Hosp; Dept. Of Clinical Onc
Shatin, , Hong Kong
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
Meldola, Emilia-Romagna, Italy
Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1
Milan, Lombardy, Italy
Az. Osp. S. Luigi Gonzaga; Malattie Apparato Respiratorio 5 Ad Indirizzo Oncologico
Orbassano, Piedmont, Italy
National Hospital Organization Kyushu Medical Center; Respiratory Internal Medicine
Fukuoka, , Japan
Kanagawa Cardiovascular and Respiratory Center; Respiratory Medicine
Kanagawa, , Japan
Yokohama Municipal Citizen'S Hospital; Respiratory Medicine
Kanagawa, , Japan
Kitasato University Hospital; Respiratory Medicine
Kanagawa, , Japan
Kyoto University Hospital, Respiratory Medicine
Kyoto, , Japan
Sendai Kousei Hospital; Pulmonary Medicine
Miyagi, , Japan
Osaka International Cancer Institute; Thoracic Oncology
Osaka, , Japan
Kansai Medical university Hospital; Thoracic Oncology
Osaka, , Japan
Osaka Habikino Medical Center
Osaka, , Japan
National Cancer Center Hospital; Thoracic Medical Oncology
Tokyo, , Japan
Toranomon Hospital; Respiratory Medicine
Tokyo, , Japan
Antoni Van Leeuwenhoek Ziekenhuis; Thoracic Oncology
Amsterdam, , Netherlands
Amphia Ziekenhuis; Afdeling Longziekten
Breda, , Netherlands
Academ Ziekenhuis Groningen; Medical Oncology
Groningen, , Netherlands
National University Hospital; National University Cancer Institute, Singapore (NCIS)
Singapore, , Singapore
National Cancer Centre; Medical Oncology
Singapore, , Singapore
Institute of Oncology Ljubljana
Ljubljana, , Slovenia
Hospital Univ Vall d'Hebron; Servicio de Oncologia
Barcelona, , Spain
ICO Badalona - Hospital Germans Trias i Pujol
Barcelona, , Spain
Hospital Universitario Virgen del Rocio; Servicio de Oncologia
Seville, , Spain
Universitaetsspital Basel; Onkologie
Basel, , Switzerland
CHUV; Departement d'Oncologie
Lausanne, , Switzerland
Kantonsspital St. Gallen; Onkologie/Hämatologie
Sankt Gallen, , Switzerland
UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie
Zurich, , Switzerland
Hacettepe Uni Medical Faculty Hospital; Oncology Dept
Ankara, , Turkey (Türkiye)
Ankara Ataturk Chest Diseases Training and Research Hospital
Ankara, , Turkey (Türkiye)
Ege University School of Medicine; Chest Diseases Department
Izmir, , Turkey (Türkiye)
Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department
Malatya, , Turkey (Türkiye)
Barts & London School of Med; Medical Oncology
London, , United Kingdom
Royal Marsden Hospital - London
London, , United Kingdom
Royal Marsden NHS Foundation Trust
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Saal J, Bald T, Eckstein M, Ralser DJ, Brossart P, Ellinger J, Holzel M, Klumper N. Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition. Lung Cancer. 2024 Mar;189:107505. doi: 10.1016/j.lungcan.2024.107505. Epub 2024 Feb 15.
Shemesh CS, Chan P, Legrand FA, Shames DS, Das Thakur M, Shi J, Bailey L, Vadhavkar S, He X, Zhang W, Bruno R. Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden. Pharmacol Res Perspect. 2020 Dec;8(6):e00685. doi: 10.1002/prp2.685.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-003330-32
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
GO28754
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.